Ruffer LLP Sells 104,917 Shares of IQVIA Holdings Inc. $IQV

Ruffer LLP lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 50.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 102,970 shares of the medical research company’s stock after selling 104,917 shares during the period. IQVIA makes up about 1.1% of Ruffer LLP’s portfolio, making the stock its 29th largest holding. Ruffer LLP owned approximately 0.06% of IQVIA worth $19,558,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. Versant Capital Management Inc increased its stake in shares of IQVIA by 6.3% in the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after purchasing an additional 53 shares during the last quarter. Private Trust Co. NA raised its stake in IQVIA by 12.5% during the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock worth $95,000 after acquiring an additional 67 shares in the last quarter. CVA Family Office LLC lifted its holdings in shares of IQVIA by 11.6% in the third quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock worth $124,000 after acquiring an additional 68 shares during the last quarter. E Fund Management Co. Ltd. boosted its stake in shares of IQVIA by 3.7% in the 2nd quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 74 shares in the last quarter. Finally, Harbor Capital Advisors Inc. increased its position in IQVIA by 2.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 2,795 shares of the medical research company’s stock worth $531,000 after purchasing an additional 78 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on IQV shares. BMO Capital Markets initiated coverage on IQVIA in a report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 target price for the company. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Sunday. Robert W. Baird set a $258.00 target price on shares of IQVIA and gave the stock an “outperform” rating in a report on Wednesday, October 29th. Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Finally, Citigroup increased their price objective on IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a report on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average price target of $251.06.

IQVIA Stock Performance

Shares of IQV opened at $239.67 on Thursday. The stock has a 50-day moving average of $230.48 and a 200-day moving average of $207.51. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The company has a market cap of $40.82 billion, a PE ratio of 32.88, a P/E/G ratio of 2.45 and a beta of 1.36.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter last year, the firm posted $2.84 earnings per share. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.